HIV 101: HIV Vaccine Candidates

Breaking Research: Read or Listen to the Latest Reports From ICAAC/IDSA 2008 >>

Brown Medical School

By HEPP News Staff

October 2001

Adapted from Johnston M.I., Flores J. Progress in HIV Vaccine Development. Current Opinion in Pharmacology. 2001:1(5):504-520. On the Web at www.niaid.nih.gov/daids/vaccine/pdf/pc1506.pdf. Additional information from Science Magazine 2001 293 (5537): 1973.

As drug-resistant HIV virus becomes more and more common, physicians will need alternative methods of treating the virus. One of the most promising of these methods is the development of a prophylactic or therapeutic vaccine. The following table provides information on vaccines currently in the development pipeline.

Vaccine Name	HIV Subtype Targeted	Producing Company	Status
gp120	B/B, B/E	VaxGen	Ongoing phase III trials in the United States and Thailand
ALVAC-HIV	B, E	Aventis Pasteur	Ongoing phase II trials in the U.S., Haiti, Brazil, Trinidad (subtype B); Thailand (sub-type E); used alone or in combination with gp120
ALVAC-HIV	A	Aventis Pasteur	Ready for Phase I trials in Uganda
Lipopeptides LP5, LP6	B	ANRS: National Agency for AIDS Research, France	Ongoing phase I trials in France
Vaccinia TBC-3B	B	Therion	Ongoing phase I trials in the U.S.
DNA-HIV	B	Apolion	Completed phase I trials
DNA-HIV, MVA-HIV	A	University of Oxford	Ongoing phase I trials in the UK and Kenya
NYVAC-HIV	B	Aventis Pasteur	Ready for phase I in the U.S.
DNA-HIV, Adenovirus HIV	B	Merck	Ongoing phase I trials in the U.S.
VaxGen Canarypox with HIV gag, protease, and env +gp120	B/E	U.S. Military, Royal Thai Govt., Mahidol U., Aventis Pasteur, VaxGen	Earliest phase III start date: Summer 2002, Thailand*
Canarypox with HIV env, gag, protease, pol, and nef, +gp120	B/?	NIH HVTN, Aventis Pasteur, VaxGen	Earliest phase III start date: December 2002, U.S., Brazil, Haiti, Peru, Trinidad (Possible: Argentina, Dominican Republic, Honduras)*
* Proposed AIDS vaccine efficacy trials (see "News Flashes"). phase I trial: first stage trial, focusing on safety and toxicity, very small cohort. phase II trial: second stage trial, measures efficacy of vaccine in small cohort. phase III trial: last stage of experimental testing, pivotal trial measures efficacy on a larger scale. gp120: recombinant HIV envelope protein. ALVAC-HIV: a recombinant canarypox virus expressing multiple HIV genes. MVA-HIV: modified vaccinia Ankara (an attenuated vaccinia vector) expressing multiple HIV genes. NYVAC-HIV: an attenuated vaccinia vector expressing multiple HIV genes. TBC-3B: an attenuated vaccinia vector expressing multiple HIV genes.

Back to the HEPP News October 2001 contents page.

This article was provided by Brown Medical School, and is a part of the publication HEPP News.

The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.